Normal human erythrocyte
phosphofructokinase (
ATP: D-
fructose-6, P-1-
phosphotransferase, EC 2.7.1.11; PFK) has recently been shown to consist of a heterogeneous mixture of five tetrameric
isozymes: M4, M3L, M2L2, ML3, and L4 (M, muscle type; L, liver type). In the light of these findings, we have investigated the molecular basis of the inherited erythrocyte PFK deficiency associated with
myopathy and
hemolysis (
Tarui disease). The propositus, a 31-yr-old male, suffered from
muscle weakness and
myoglobinuria on exertion. He showed mild
erythrocytosis despite laboratory evidence of
hemolysis. In his erythrocytes a metabolic crossover point was found at the level of PFK;
2,3-diphosphoglycerate (2,3-DPG) was also significantly reduced. The PFK from the patient's erythrocytes consisted exclusively of the L4
isozyme, and there was a complete absence of the other four. The leukocyte and platelet PFKs from the patient showed normal activities, chromatographic profiles, and precipitation with anti-M4 antibody. These studies provide direct evidence that in
Tarui disease the M-type subunits are absent; but the liver- and platelet-type subunits of PFK are unaffected. The paradox of mild
erythrocytosis despite
hemolysis reflects the decreased production of
2,3-DPG.